Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Division of Cardiovascular Medicine, Brown University, Providence, Rhode Island.
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):70-81. doi: 10.1002/ccd.28062. Epub 2018 Dec 28.
This updated meta-analysis evaluated outcomes with multi-vessel (MV-PCI) vs culprit lesion-only percutaneous coronary intervention (CL-PCI), in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS).
There is considerable debate regarding the optimal revascularization strategy in patients with AMI and CS, particularly regarding management of non-culprit lesions.
Databases were searched for studies comparing MV-PCI and CL-PCI in patients with AMI and CS. The primary outcome of interest was short-term all-cause mortality. Secondary outcomes included long-term mortality, repeat revascularization and myocardial reinfarction. Safety outcomes were stroke, acute renal failure and major bleeding. Pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated using random-effects models.
Our meta-analysis consisting of 14 studies (13 observational, 1 RCT) involving 8,552 patients showed that in comparison to CL-PCI, MV-PCI was associated with similar short-term mortality (OR 1.14; 95% CI 0.9-1.43), as well as similar long-term mortality (OR 0.94; 95% CI 0.68-1.28). There was no significant difference in the risk of myocardial reinfarction (OR 1.19; 95% CI 0.76-1.86), or repeat revascularization (OR 0.79; 95% CI 0.41-1.55) between the two groups. Compared to CL-PCI, MV-PCI was associated with a similar risk of bleeding (OR 1.13; 95% CI 0.91-1.40) and stroke (OR 1.28; 95% CI 0.84-1.96), but a higher risk of developing renal failure (OR 1.32; 95% CI 1.05-1.65).
Our meta-analysis suggests that there is a higher risk of renal failure with no additional benefit in efficacy outcomes with MV-PCI, compared to CL-PCI in patients with AMI and CS.
本更新的荟萃分析评估了多支血管(MV-PCI)与罪犯病变单纯经皮冠状动脉介入治疗(CL-PCI)治疗急性心肌梗死(AMI)合并心源性休克(CS)患者的结局。
在 AMI 合并 CS 患者中,对于最佳血运重建策略存在相当大的争议,特别是对于非罪犯病变的处理。
检索数据库以比较 AMI 和 CS 患者的 MV-PCI 和 CL-PCI。主要观察终点为短期全因死亡率。次要终点包括长期死亡率、再次血运重建和心肌再梗死。安全性终点为卒中和急性肾功能衰竭和大出血。使用随机效应模型估计汇总比值比(OR)和 95%置信区间(CI)。
我们的荟萃分析包括 14 项研究(13 项观察性研究,1 项 RCT),共纳入 8552 例患者,结果表明,与 CL-PCI 相比,MV-PCI 与短期死亡率相似(OR 1.14;95%CI 0.9-1.43),长期死亡率也相似(OR 0.94;95%CI 0.68-1.28)。两组间心肌再梗死(OR 1.19;95%CI 0.76-1.86)或再次血运重建(OR 0.79;95%CI 0.41-1.55)风险无显著差异。与 CL-PCI 相比,MV-PCI 与相似的出血风险(OR 1.13;95%CI 0.91-1.40)和卒中风险(OR 1.28;95%CI 0.84-1.96)相关,但发生急性肾衰的风险更高(OR 1.32;95%CI 1.05-1.65)。
我们的荟萃分析表明,与 CL-PCI 相比,MV-PCI 治疗 AMI 合并 CS 患者的肾衰竭风险较高,而疗效结果无额外获益。